TAK 272

Drug Profile

TAK 272

Alternative Names: TAK-272

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator Takeda
  • Class Antihypertensives
  • Mechanism of Action Renin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Diabetic nephropathies
  • Discontinued Hypertension

Most Recent Events

  • 01 Aug 2016 Takeda completes a phase II trial in Diabetic nephropathies in Japan (NCT02332824)
  • 01 Jul 2016 Takeda completes a phase I trial in patients with renal or hepatic impairment in Japan (PO) (NCT02367872; JapicCTI-152790)
  • 30 Jul 2015 Discontinued - Phase-I for Hypertension in Japan (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top